Results presented in June 2010 at the American Society of Clinical Oncology annual conference demonstrated that single agent CAL-101 treatment in individuals with relapsed or refractory indolent non-Hodgkin’s lymphoma , mantle cell lymphoma , and chronic lymphocytic leukemia led to overall response prices of 57 %, 67 % and thirty %, respectively. Furthermore, 94 % of individuals with CLL had greater than 50 % reduction in their lymph node disease, demonstrating a high amount of biologic activity. Overall, CAL-101 was generally well tolerated.The patients signed up for this trial had been randomized to get treatment with the FOLFOX4 routine with or without Avastin. Randomization to a third arm of the analysis evaluating single-agent Avastin was suspended in March 2003 on the suggestion of the info Monitoring Committee overseeing the analysis when overview of early outcomes suggested that general survival for patients for the reason that group may be lower in comparison to that of sufferers treated on the additional two arms. Results out of this treatment arm haven’t yet been disclosed. An initial assessment of the security profile recommended that Avastin could possibly be combined securely with FOLFOX4 and treatment toxicities seen in this research were in keeping with adverse events seen in other medical trials where Avastin was coupled with chemotherapy.